New opportunities in China, from drug development to commercialization
Date: Monday, 12 March 2018
Time: 09:00 - 10:30
Location: Room E107/108
Western companies, along with the rest of the world have been watching the extraordinary trajectory of both public and private spending on research and development (R&D) into pharmaceuticals in China. While it may be some time before we see the full impact from the surge in patenting, a multitude of Chinese home-grown biopharmaceutical companies are already capturing the attention of global markets. Coupled with recent regulatory changes, China is now positioned as an ideal R&D and commercialization partner for drug assets. This panel will discuss the impact of recent changes in China, partnering with companies in a future pharmaceutical R&D super power, and as a financial hub for economic growth.
Alex Fink, Managing Director Commercial Strategy & Planning (Europe)
BARRY MORGAN - Chief Scientific Officer at HitGen Ltd.
JONATHAN WANG - VP, Head of Business Development at Zai Lab
MARIETTA WU - Managing Director at Quan Capital
Government of Amsterdam, North Holland